Mallinckrodt Plc Announces New Drug Application Accepted For Review By FDA

Thursday, 22 Aug 2013 07:00am EDT 

Mallinckrodt Plc announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for MNK-395. MNK-395 is referred to in the application as PENNSAID (diclofenac sodium topical solution) 2% w/w, studied in the treatment of the pain of osteoarthritis of the knee. 

Latest Developments for Mallinckrodt Inc

Related Company News